Literature DB >> 9366003

HIV/AIDS risks as a consequence of schizophrenia.

I I Gottesman1, C S Groome.   

Abstract

Given both the rapid rise in the prevalence of HIV infection among adolescent and adult males (0.6%) and females (0.1%) in the United States from 1984 to 1992 and the associations among HIV, injection drug abuse, homosexuality, and sexual promiscuity, it is important to determine whether individuals diagnosed with schizophrenia are at a higher than average risk of HIV infection. Stereotypes from the recent past about sexuality in both male and female patients were examined as an integral part of a literature review. Data from a dozen or so studies conducted since 1990 confirm and strengthen the impressions that persons with schizophrenia should be considered a group with a much higher than average risk for developing HIV/AIDS and that they have special needs for protection as a public health measure. Mental health service providers need to be aware of these findings.

Entities:  

Mesh:

Year:  1997        PMID: 9366003     DOI: 10.1093/schbul/23.4.675

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  13 in total

1.  Use of Medicaid data to explore community characteristics associated with HIV prevalence among beneficiaries with schizophrenia.

Authors:  James Walkup; Ayse Akincigil; Donald R Hoover; Michele J Siegel; Shahla Amin; Stephen Crystal
Journal:  Public Health Rep       Date:  2011 Sep-Oct       Impact factor: 2.792

Review 2.  Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia.

Authors:  Anna M Fineberg; Lauren M Ellman
Journal:  Biol Psychiatry       Date:  2013-02-12       Impact factor: 13.382

3.  Causal Pathways Between Severe Mental Illness and Behaviors Related to HIV: Patient Perspectives.

Authors:  Puneet Chawla Sahota; Brigid E Cakouros; Rachel Russell; Michael Hassler; Michael B Blank; Frances K Barg
Journal:  Community Ment Health J       Date:  2019-09-18

4.  Increasing quality of life and reducing HIV burden: the PATH+ intervention.

Authors:  Michael B Blank; Michael Hennessy; Marlene M Eisenberg
Journal:  AIDS Behav       Date:  2014-04

Review 5.  Treatment considerations for HIV-infected individuals with severe mental illness.

Authors:  Michael B Blank; Seth Himelhoch; James Walkup; Marlene M Eisenberg
Journal:  Curr HIV/AIDS Rep       Date:  2013-12       Impact factor: 5.071

6.  The Risk of Sexually Transmitted Infections Following First-Episode Schizophrenia Among Adolescents and Young Adults: A Cohort Study of 220 545 Subjects.

Authors:  Chih-Sung Liang; Ya-Mei Bai; Ju-Wei Hsu; Kai-Lin Huang; Nai-Ying Ko; Hsuan-Te Chu; Ta-Chuan Yeh; Shih-Jen Tsai; Tzeng-Ji Chen; Mu-Hong Chen
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

7.  A multisite study of the prevalence of HIV with rapid testing in mental health settings.

Authors:  Michael B Blank; Seth S Himelhoch; Alexandra B Balaji; David S Metzger; Lisa B Dixon; Charles E Rose; Emeka Oraka; Annet Davis-Vogel; William W Thompson; James D Heffelfinger
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

8.  Coercion or Caring: The Fundamental Paradox for Adherence Interventions for HIV+ People with Mental Illness.

Authors:  Marlene M Eisenberg; Michael Hennessy; Donna Coviello; Nancy Hanrahan; Michael B Blank
Journal:  AIDS Behav       Date:  2017-06

9.  Hepatitis B and C among veterans on a psychiatric ward.

Authors:  James H Tabibian; Donna A Wirshing; Joseph M Pierre; Lisa H Guzik; Michael D Kisicki; Itai Danovitch; Shirley J Mena; William C Wirshing
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

10.  A descriptive analysis of HIV prevalence, HIV service uptake, and HIV-related risk behaviour among patients attending a mental health clinic in Rural Malawi.

Authors:  Kinke Lommerse; Robert C Stewart; Queen Chilimba; Thomas van den Akker; Crick Lund
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.